Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ojemda

(oh-JEM-dah)
A drug used to treat children aged 6 months and older with low-grade glioma (a type of brain tumor) that has certain mutations (changes) in the BRAF gene. It is used in patients whose tumor came back or did not get better after treatment with other therapy. It is also being studied in the treatment of other types of cancer. Ojemda blocks certain proteins made by the mutated BRAF gene, which may help keep tumor cells from growing. It is a type of kinase inhibitor. Also called tovorafenib.
More Information
Search NCI's Dictionary of Cancer Terms